pentobarbital will lessen the extent or result of roflumilast by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not proposed; potent cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and will lessen the therapeutic successpentobarbital decreases effects of hemin by pharmacodynamic an